Incyte Corporation (INCY)
| Market Cap | 18.81B |
| Revenue (ttm) | 5.36B |
| Net Income (ttm) | 1.43B |
| Shares Out | 199.01M |
| EPS (ttm) | 7.06 |
| PE Ratio | 13.56 |
| Forward PE | 12.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,414,628 |
| Open | 94.75 |
| Previous Close | 95.72 |
| Day's Range | 92.79 - 97.96 |
| 52-Week Range | 57.77 - 112.29 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 104.05 (+10.06%) |
| Earnings Date | Apr 28, 2026 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $104.05, which is an increase of 10.06% from the latest price.
News
Incyte beats first-quarter estimates on strong demand for cancer drugs
Drugmaker Incyte beat analysts' estimates for first-quarter profit and revenue on Tuesday, partly helped by strong demand for its cancer treatments, including Jakafi and Minjuvi.
Incyte Earnings Call Transcript: Q1 2026
Q1 2026 saw 20% net sales growth and 21% total revenue growth, driven by strong demand across all products and geographies. Multiple late-stage pipeline advances and regulatory milestones were achieved, with four new product launches expected in the next year.
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates.
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer.
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO26--Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--1Q Alert.
Incyte's skin disease drug shows long-term symptom relief in late-stage trials
Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials.
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2026--Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting.
Incyte Announces Executive Leadership Appointments
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Executive Leadership Appointments.
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2026--Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Lab...
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Uni...
Incyte Transcript: Barclays 28th Annual Global Healthcare Conference
The discussion highlighted a diversified pipeline with major advances in hematology, oncology, and immunology. Key programs are progressing to pivotal trials, with new formulations and rapid-acting therapies aiming to drive growth beyond Jakafi's loss of exclusivity.
Incyte Transcript: Leerink Global Healthcare Conference 2026
Management outlined a strategy focused on expanding the core business beyond Jakafi, advancing a robust pipeline in hematology and immunology, and launching new products like povorcitinib. INCA33989, a CALR antibody, is positioned to transform MPN treatment with pivotal trials starting in 2024.
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for First-Line Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC).
Incyte Transcript: TD Cowen 46th Annual Health Care Conference
Growth is expected from core assets and late-stage pipeline, with Opzelura, Monjuvi, and Niktimvo as key drivers. Regulatory milestones for INCB000928 and new launches like XR and povorcitinib are set to shape the next several years.
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is t...
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conferenc...
Incyte weak 2026 revenue forecast heightens Jakafi patent concerns
Incyte forecast annual sales below Wall Street estimates on Tuesday with its key growth driver Opzelura expected to underperform, raising concerns about the drugmaker's ability to offset looming paten...
Incyte Earnings Call Transcript: Q4 2025
2025 saw strong revenue and sales growth across all segments, with core business ex-Jakafi up 53% and major product launches and regulatory milestones achieved. 2026 guidance projects continued double-digit growth, robust pipeline advancement, and increased operating leverage.
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Fourth Quarter and Full Year 2025 Financial Results.
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC).
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tue...
Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity
Bill Meury, Incyte president and CEO, joins 'Fast Money' to talk potential M&A, its growth trajectory, its product pipeline, and more.
Incyte Transcript: 44th Annual J.P. Morgan Healthcare Conference
Management outlined a strategy to transition from reliance on Jakafi to a diversified portfolio in hematology, oncology, and immunology, with strong sales growth and a robust late-stage pipeline. Key assets are advancing toward pivotal trials, and disciplined expense management is set to support long-term growth beyond 2029.